Novartis (NVS)

Executive Summary

Novartis is a leading global pharmaceutical company with a strong portfolio of innovative medicines across oncology, immunology, neuroscience, and cardiovascular diseases. In 2025, the company demonstrated robust growth driven by key products such as Entresto, Cosentyx, and Kisqali, with total revenues exceeding $50 billion. Novartis continues to invest heavily in R&D, focusing on targeted therapies and advanced platforms like radioligand therapy and gene therapy. The company's strategic divestitures, including the spin-off of Sandoz, have sharpened its focus on innovative medicines, improving margins and enabling reinvestment into high-potential pipelines. Looking ahead, Novartis has several late-stage pipeline assets that could drive future growth. Key upcoming catalysts include regulatory decisions and clinical data readouts for iptacopan in complement-mediated diseases, remibrutinib in chronic spontaneous urticaria, and Kisqali in broader breast cancer indications. With a strong balance sheet and a disciplined capital allocation strategy, Novartis is well-positioned to deliver sustainable long-term value to shareholders.

Upcoming Catalysts (preview)

• Q4 2026iptacopan FDA approval for C3 glomerulopathy80% success
• H2 2026remibrutinib phase 3 results in chronic spontaneous urticaria75% success
• Q3 2026Kisqali FDA approval for early breast cancer adjuvant indication90% success